Monopar Therapeutics MNPR Stock
Monopar Therapeutics Price Chart
Monopar Therapeutics MNPR Financial and Trading Overview
| Monopar Therapeutics stock price | 72 USD |
| Previous Close | 72.68 USD |
| Open | 72.93 USD |
| Bid | 69.8 USD x 300 |
| Ask | 70.28 USD x 100 |
| Day's Range | 67.7 - 73.48 USD |
| 52 Week Range | 50.07 - 124.82 USD |
| Volume | 203.21K USD |
| Avg. Volume | 157.5K USD |
| Market Cap | 483.28M USD |
| Beta (5Y Monthly) | 1.615 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 129.92 USD |
MNPR Valuation Measures
| Enterprise Value | 347.37M USD |
| Trailing P/E | N/A |
| Forward P/E | -27.243008 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.4959943 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Monopar Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.615 |
| 52-Week Change | -6.82% |
| S&P500 52-Week Change | 12.28% |
| 52 Week High | 124.82 USD |
| 52 Week Low | 50.07 USD |
| 50-Day Moving Average | 83.52 USD |
| 200-Day Moving Average | 77.24 USD |
MNPR Share Statistics
| Avg. Volume (3 month) | 157.5K USD |
| Avg. Daily Volume (10-Days) | 169.54K USD |
| Shares Outstanding | 6.71M |
| Float | 4.47M |
| Short Ratio | 7.51 |
| % Held by Insiders | 23.46% |
| % Held by Institutions | 95.49% |
| Shares Short | 1.1M |
| Short % of Float | 24.05% |
| Short % of Shares Outstanding | 16.44% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.64% |
| Return on Equity (ttm) | -19.49% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -17844746 USD |
| Diluted EPS (ttm) | -2.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 134.3M USD |
| Total Cash Per Share (mrq) | 20.01 USD |
| Total Debt (mrq) | 205.66K USD |
| Total Debt/Equity (mrq) | 0.16 USD |
| Current Ratio (mrq) | 33.556 |
| Book Value Per Share (mrq) | 20.595 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12181947 USD |
| Levered Free Cash Flow (ttm) | -6098616 USD |
Profile of Monopar Therapeutics
| Country | United States |
| State | IL |
| City | Wilmette |
| Address | 1000 Skokie Boulevard |
| ZIP | 60091 |
| Phone | 847 388 0349 |
| Website | https://www.monopartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Q&A For Monopar Therapeutics Stock
What is a current MNPR stock price?
Monopar Therapeutics MNPR stock price today per share is 72 USD.
How to purchase Monopar Therapeutics stock?
You can buy MNPR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Monopar Therapeutics?
The stock symbol or ticker of Monopar Therapeutics is MNPR.
Which industry does the Monopar Therapeutics company belong to?
The Monopar Therapeutics industry is Biotechnology.
How many shares does Monopar Therapeutics have in circulation?
The max supply of Monopar Therapeutics shares is 6.78M.
What is Monopar Therapeutics Price to Earnings Ratio (PE Ratio)?
Monopar Therapeutics PE Ratio is now.
What was Monopar Therapeutics earnings per share over the trailing 12 months (TTM)?
Monopar Therapeutics EPS is -2.44 USD over the trailing 12 months.
Which sector does the Monopar Therapeutics company belong to?
The Monopar Therapeutics sector is Healthcare.
Monopar Therapeutics MNPR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25136.27 USD — |
-0.91
|
7.74B USD — | 24872.41 USD — | 25423.09 USD — | — - | 7.74B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
113.05 USD — |
-1.08
|
— — | 111.72 USD — | 114.38 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.29 USD — |
-0.34
|
— — | 1358.68 USD — | 1373.65 USD — | — - | — — |
